31191-46-5

Basic information

• Product Name: 2-(3-bromopropoxy)-1-chloro-4-nitrobenzene
• CAS NO: 31191-46-5
• Molecular Formula: C₉H₉BrClNO₃
• Molecular Weight: 294.5297
• Mol File: 31191-46-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 390.8°C at 760 mmHg
• Flash Point: 190.2°C
• Density: 1.605g/cm³
• Vapor Pressure: 5.79E-06mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: 2-(3-bromopropoxy)-1-chloro-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-bromopropoxy)-1-chloro-4-nitrobenzene(31191-46-5)
• EPA Substance Registry System: 2-(3-bromopropoxy)-1-chloro-4-nitrobenzene(31191-46-5)

Safety Data

• Hazardous Substances Data: 31191-46-5(Hazardous Substances Data)

Usage

Type of compound

Nitroaromatic compound

Core structure

1-chloro-4-nitrobenzene

Substituent

3-bromopropoxy

Uses

Intermediate in organic synthesis (e.g. production of pharmaceuticals and agrochemicals), building block in the synthesis of functional materials, potential applications in medicinal chemistry and development of dyes/pigments/specialty chemicals

Pharmacological properties

Not specified in the provided material

Upstream product

• 619-10-3 5-nitro-2-chlorophenol 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 1349820-64-9 6-chloro-3-ethyl-2-methyl-7-[3-(4-phenylpiperazin-1-yl)propoxy]-1H-quinolin-4-one 
• 1349821-48-2 4-chloro-3-[3-(4-phenylpiperazin-1-yl)propoxy]phenylamine 
• 1349821-46-0 1-[3-(2-chloro-5-nitrophenoxy)propyl]-4-phenylpiperazine 
• 31185-44-1 4-[3-(2-Chloro-5-nitro-phenoxy)-propoxy]-benzenesulfonyl fluoride 

Relevant articles and documents

4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance

Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a Plasmodium infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a Plasmodium infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.